MYGN - Myriad Genetics, Inc.
| Previous Close | 29.68 |
| Open | 29.77 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 2900 |
| Day's Range | 29.53 - 30.30 |
| 52 Week Range | 22.04 - 48.40 |
| Volume | 378,364 |
| Avg. Volume | 1,375,473 |
| Market Cap | 2.203B |
| Beta (3Y Monthly) | 1.44 |
| PE Ratio (TTM) | 497.00 |
| EPS (TTM) | 0.06 |
| Earnings Date | Nov. 4, 2019 - Nov. 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.25 |
- GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN
NEW YORK, Oct. 15, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) and.
- GlobeNewswire
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important November 26th Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYGN
NEW YORK, Oct. 14, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. (NASDAQ: MYGN) from September 2,.
- Business Wire
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors who purchased securities between September 2, 2016 and August 13, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On August 13, 2019, after the market closed, Myriad disclosed that “[u]nfortunately, revenue in the fourth quarter was two percent below expectations largely due to lower reimbursement for [the Company’s] expanded carrier screening test [called Foresight].” Additionally, the Company revealed that, since at least late 2018, the U.S. Food and Drug Administration (“FDA”) had increasingly questioned the claims of marketed genetics tests, such as Myriad’s GeneSight.
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of TXT, MO and MYGN
NEW YORK, NY / ACCESSWIRE / October 13, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - MYGN
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (MYGN) and certain of its officers. The class action, filed in United States District Court, for the District of Utah, and indexed under 19-cv-00707, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Myriad securities between September 2, 2016 and August 13, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of DBX, MO and MYGN
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Investors Affected: on behalf of all persons who purchased Dropbox Class A common stock pursuant or traceable to the registration statement issued in connection with the Company’s March 23, 2018 initial public offering.
- GlobeNewswire
INVESTOR ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: November 26, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Myriad Genetics, Inc. (“Myriad” or the “Company”) (MYGN) and certain of its officers, on behalf of shareholders who purchased Myriad securities between September 2, 2016 through August 13, 2019, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PS, VAL and MYGN
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- Business Wire
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) securities between September 2, 2016 and August 13, 2019, inclusive (the “Class Period”). Investors suffering losses on their Myriad investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MDP, MYGN and UBER
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- ACCESSWIRE
INVESTOR ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Deadline: November 26, 2019
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (MYGN) and certain of its officers, on behalf of shareholders who purchased Myriad securities between September 2, 2016 through August 13, 2019, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PS, MTCH and MYGN
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in Pluralsight, Inc. According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections.
- ACCESSWIRE
MYGN SHAREHOLDER REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm
Class-action law firm urges MYGN investors who have suffered losses of $50K+ to submit a loss form now to learn if they qualify to recover their investment losses. SAN FRANCISCO, CA / ACCESSWIRE / Ocrober ...
- ACCESSWIRE
SHAREHOLDER ALERT: WTRH CVET MYGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
- Business Wire
Myriad Genetics Investors: Filing Deadline in MYGN Class Action – Contact Lieff Cabraser
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Myriad Genetics, Inc. (“Myriad” or the “Company”) (MYGN) between September 2, 2016 and August 13, 2019, inclusive (the “Class Period”). If you purchased or otherwise acquired the securities of Myriad during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 26, 2019. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
- ACCESSWIRE
CLASS ACTION UPDATE for PS, TME and MYGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
- ACCESSWIRE
INVESTOR ALERT - Myriad Genetics, Inc. (MYGN) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Plaintiff Deadline: November 26, 2019
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Myriad Genetics, Inc. ("Myriad" or the "Company") (MYGN) and certain of its officers, on behalf of shareholders who purchased Myriad securities between September 2, 2016 through August 13, 2019, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
- Simply Wall St.
Does The Myriad Genetics, Inc. (NASDAQ:MYGN) Share Price Fall With The Market?
If you own shares in Myriad Genetics, Inc. (NASDAQ:MYGN) then it's worth thinking about how it contributes to the...
- ACCESSWIRE
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VRAY, CVET and MYGN
CEDARHURST, NY / ACCESSWIRE / October 9, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eldorado Resorts, Sundial, Tencent, and Myriad Genetics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eldorado Resorts, Inc. (ERI), Sundial Growers, Inc. (NASDAQ:SNDL), Tencent Music Entertainment Group (TME), and Myriad Genetics, Inc. (MYGN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- ACCESSWIRE
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TME, CVET and MYGN
CEDARHURST, NY / ACCESSWIRE / October 9, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- GlobeNewswire
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in VAL, NTAP, and MYGN of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of VAL, NTAP, and MYGN. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
- ACCESSWIRE
SHAREHOLDER ALERT: IFF MO MYGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 8, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
- GlobeNewswire
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Myriad Genetics, Inc.– MYGN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Myriad Genetics, Inc. (MYGN) from September 2, 2016 through August 13, 2019 inclusive (the “Class Period”). The lawsuit seeks to recover damages for Myriad Genetics, Inc. investors under the federal securities laws. To join the class action, go to http://pawarlawgroup.com/cases/myriad-genetics-inc/ or call Vik Pawar, Esq.
